Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
Abstract Background: At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We…
Dominic Oliver
Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial
Abstract In patients with schizophrenia, cannabis use exacerbates symptoms and can lead to a relapse of psychosis. Some experimental studies…
Psychosis associated with cannabis withdrawal: systematic review and case series
Abstract Background: Abrupt cessation of heavy cannabis use can cause a withdrawal syndrome characterised by irritability, anxiety, insomnia, reduced appetite…
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample
Abstract Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The…
Novel Lipid Formulation Increases Absorption of Oral Cannabidiol (CBD)
Abstract Background: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders.…
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study
Abstract Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system.…
Cannabidiol does not attenuate acute delta‐9‐tetrahydrocannabinol‐induced attentional bias in healthy volunteers: A randomised, double‐blind, cross‐over study
Abstract Aims: To test how attentional bias and explicit liking are influenced by delta‐9‐tetrahydrocannabinol (THC) and whether these effects are…
Influence of cannabis use on incidence of psychosis in people at clinical high risk
Abstract Aims: Evidence for case–control studies suggests that cannabis use is a risk factor for the development of psychosis. However,…
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
Abstract As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful…
Acceptability of cannabidiol in patients with psychosis
Abstract Background: Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile…